Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1855 Target Snapshot

Gonadotropin-releasing hormone receptor · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,768Compounds
301Assays
16Approved Drugs
3,058.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Gonadotropin-releasing hormone receptor shows approved-linked disease relevance led by endometriosis. 5 more disease programs remain visible in the same review block. 9 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P30968. Start with endometriosis, then reuse UniProt P30968 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with endometriosis, then reuse UniProt P30968 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 9 linked drugs
Open source guide
Disease program
endometriosis

Gonadotropin-releasing hormone receptor shows approved-linked disease relevance led by endometriosis. 5 more disease programs remain visible in the same review block. 9 linked drugs remain visible in the same block.

Start review with endometriosis because it currently carries approved-linked support. Linked drugs include ELAGOLIX, ELAGOLIX SODIUM, LEUPROLIDE ACETATE, LINZAGOLIX. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 9 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Gonadotropin-releasing hormone receptor as ChEMBL target CHEMBL1855, mapped to UniProt P30968. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Gonadotropin-releasing hormone receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1855
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P30968
Gonadotropin-releasing hormone receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Gonadotropin-releasing hormone receptor is the right protein anchor across sources, using UniProt P30968 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why endometriosis is currently framed as approved-linked support. It currently carries 9 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameGonadotropin-releasing hormone receptor
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP30968
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelGonadotropin-releasing hormone receptor
UniProt AccessionP30968
Component TypeProtein
Sequence Length328 aa

Gonadotropin-releasing hormone receptor

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Gonadotropin-releasing hormone receptor, mapped to UniProt P30968. Sequence length is 328 aa.

Mapped IDP30968
Review nameGonadotropin-releasing hormone receptor
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Gonadotropin-releasing hormone receptor shows approved-linked disease relevance led by endometriosis. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
endometriosis
9 linked drugs · 9 direct · 9 efficacy
Linked drugELAGOLIX
Linked drugELAGOLIX SODIUM
Linked drugLEUPROLIDE ACETATE
Linked drugLINZAGOLIX
Approved-linked Approved
prostate adenocarcinoma
8 linked drugs · 8 direct · 8 efficacy
Linked drugBUSERELIN
Linked drugDEGARELIX ACETATE
Linked drugGONADORELIN ACETATE
Linked drugGOSERELIN ACETATE
Approved-linked Approved
breast cancer
5 linked drugs · 5 direct · 5 efficacy
Linked drugGONADORELIN ACETATE
Linked drugGOSERELIN ACETATE
Linked drugLEUPROLIDE ACETATE
Linked drugTRIPTORELIN PAMOATE
Approved-linked Approved
metastatic prostate cancer
5 linked drugs · 5 direct · 5 efficacy
Linked drugGONADORELIN ACETATE
Linked drugGOSERELIN ACETATE
Linked drugLEUPROLIDE ACETATE
Linked drugRELUGOLIX
Approved-linked Approved
prostate cancer
5 linked drugs · 5 direct · 5 efficacy
Linked drugDEGARELIX ACETATE
Linked drugHISTRELIN ACETATE
Linked drugLEUPROLIDE ACETATE
Linked drugLEUPROLIDE MESYLATE
Approved-linked Approved
prostate carcinoma
5 linked drugs · 5 direct · 5 efficacy
Linked drugDEGARELIX ACETATE
Linked drugGONADORELIN ACETATE
Linked drugGOSERELIN ACETATE
Linked drugLEUPROLIDE ACETATE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with endometriosis because it currently carries approved-linked support. Linked drugs include ELAGOLIX, ELAGOLIX SODIUM, LEUPROLIDE ACETATE, LINZAGOLIX. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseendometriosis
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

16
Approved
4
Phase II
Assay Mix

Activity Type Distribution

IC502,131.0
KI880.0
KD47.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL22055 10.22 IC50 0.06 Clinical
CHEMBL379629 10.22 IC50 0.06 Preclinical
CHEMBL435167 10.15 IC50 0.07 Preclinical
CHEMBL210294 10.15 IC50 0.07 Preclinical
CHEMBL377396 10.15 IC50 0.07 Preclinical
CHEMBL1800155 10.15 IC50 0.07 Preclinical
CHEMBL1800156 10.15 IC50 0.07 Preclinical
CHEMBL1800663 10.15 IC50 0.07 Preclinical
CHEMBL1800157 10.1 IC50 0.08 Preclinical
CHEMBL1800159 10.1 IC50 0.08 Approved
Distribution

pChEMBL Value Distribution

76
5.0
143
5.5
248
6.0
315
6.5
385
7.0
395
7.5
428
8.0
373
8.5
307
9.0
89
9.5
pChEMBL
Approved Drugs

Approved Drugs

LINZAGOLIX
CHEMBL3668014
Approved 2022
Properties Compare Identifier
RELUGOLIX
CHEMBL1800159
Approved 2019
Properties Compare Identifier
ELAGOLIX SODIUM
CHEMBL502182
Approved 2018
Properties Compare Identifier
DEGARELIX
CHEMBL415606
Approved 2008
Properties Compare Identifier
ABARELIX
CHEMBL1252
Approved 2003
Properties Compare Identifier
CETRORELIX
CHEMBL1200490
Approved 1999
Properties Compare Identifier
GANIRELIX ACETATE
CHEMBL5314377
Approved 1999
Properties Compare Identifier
LEUPROLIDE
CHEMBL1201199
Approved 1985
Properties Compare Identifier
GONADORELIN
CHEMBL1007
Approved 1982
Properties Compare Identifier
Assay Landscape

Assay Landscape

301
Total Assays
1,433
Tested Compounds
2
Assay Types
Binding — 247 assays, 1,433 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 166 634 7.8
cell-based format 71 767 7.4
assay format 6 18 9.0
cell membrane format 2 4 8.0
organism-based format 2 10 6.9
Functional — 54 assays, 549 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 37 437 7.8
assay format 16 111 7.8
single protein format 1 1 9.0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine